BP1200 / BrightPath Biotherap - LARVOL DELTA

A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy (AACR 2022) - "The novel anti-human CD73 antibody, BP1200, ameliorates immunosuppressive TME caused by adenosine and enhances antitumor immune responses. The combination of BP1200 and immune-checkpoint inhibitors for cancer treatment will be a promising therapeutic option in clinical practice."

Biomarker • Clinical • IO biomarker • Tumor microenvironment • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • NT5E

[VIRTUAL] A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy (ESMO 2021) - "BP1200 is a humanized anti-CD73 antibody that attenuates the AMP hydrolysis activity of CD73. By blocking AMP hydrolysis, BP1200 ameliorates adenosine mediated immunosuppressive TME and activates T-cell activity. The combination of BP1200 and immunocheckpoint antibody for cancer treatment will be a promising regimen in clinical practice."

Biomarker • Clinical • Tumor microenvironment • Oncology • CD34 • CD73 • NT5E

BrightPath Presents Preclinical Data on a CD73 antagonist antibody at ESMO 2021 (BrightPath Biotherapeutics Press Release) - “BrightPath Biotherapeutics…announced data presentations from its immuno-oncology pipeline at the European Society for Medical Oncology (ESMO) 2021 Congress, Sept. 16-21, 2021. The abstract featuring data on a CD73 antagonist therapeutic antibody, BP1200 will be shared in a virtual poster viewing session.”

Preclinical • Oncology